secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2022-07-06T23:59:59+00:00
Accession:  0001367644-22-000105
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions appoints Sujata Dayal to board; compliance expert joins committees
--------------------------------------------------------------------------------

- Sujata Dayal appointed Class II director effective July 15, 2022; term expires at 2023 annual meeting.
- Also appointed to Nominating and Corporate Governance Committee and Special Committee on Manufacturing and Quality Oversight.
- Dayal is VP and Global Chief Compliance Officer at Medline Industries; previously VP healthcare compliance at Johnson & Johnson.
- She will receive an initial equity award of $375,000 in RSUs vesting one-third per year for three years.
- Dayal is an attorney with expertise in healthcare compliance, regulatory law, and anti-corruption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000105/0001367644-22-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000105/ebs-20220701.htm
  HTML page:      https://secwatch.observer/filing/0001367644-22-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer